Avadel Pharma (AVDL) Tops Q3 EPS by 11c

Avadel Pharma (NASDAQ: AVDL) reported Q3 EPS of $0.09, $0.11 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $39.7 million versus the consensus estimate of $37.71 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.

You May Also Be Interested In

• Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
• S&P 500 above 8,000 in 2026 now looks ambitious, Citi says
• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance